Answers are grounded in this paper and cite their sources.
= 0.79). Our results confirm that the modular ZnONRs-peptide biosensor platform is not only sensitive and specific but also versatile, scalable, and rapidly adaptable to future SARS-CoV-2 variants or other emerging pathogens. This approach provides a clinically relevant, point-of-care alternative for serological assessment and monitoring of variant-specific immune responses.
No takes yet. Share an insight, caveat, or question.
Nunez et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: